David C. Hastings - 20 Jan 2022 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)

Role
Chief Financial Officer
Signature
David C Hastings
Issuer symbol
ABUS
Transactions as of
20 Jan 2022
Net transactions value
+$800,850
Form type
4
Filing time
20 Jan 2022, 16:55:10 UTC
Previous filing
19 Jan 2022
Next filing
22 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABUS Stock Option (Right to Buy) Award $800,850 +285,000 $2.81 285,000 20 Jan 2022 Common Shares 285,000 $2.81 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These stock options will vest and become exercisable 1/48th each month over the four year period.